Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma
Published in: Annals of Hematology
Access to document 10.1007/s00277-018-3233-9 document
Marcel Nijland, Tom van Meerten, Annika Seitz, Gerwin Huls, Robby Kibbelaar, Lydia Visser, Anke van den Berg, Arjan Diepstra
Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells
Published in: The American Journal of Pathology
Access to document 10.1016/j.ajpath.2018.01.018 document
miRNAs are small noncoding RNAs involved in the posttranscriptional regulation of gene expression. Deregulated miRNA levels have been linked to Burkitt lymphoma (BL) pathogenesis. To date, the number of known pathogenesis-related miRNA-target gene interactions is limited. Here, we determined for the first time the miRNA targetomes of primary BL tumors and normal B cells. AG02-RNA immunoprecipitation of two frozen diagnostic BL tissue samples and three CD19(+) B-cell samples isolated from routinely removed tonsils showed distinct miRNA targetomes of BL and normal B cells. In contrast to normal B...
Agnieszka Dzikiewicz-Krawczyk, Arjan Diepstra, Bea Rutgers, Gertrud Kortman, D. de Jong, Jasper Koerts, Marian Bulthuis, Tineke van der Sluis, Annika Seitz, Lydia Visser, Klaas Kok, Joost Kluiver, Anke van den Berg
Rapid BRAF mutation tests in patients with advanced melanoma: Comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform
Published in: Melanoma Research
Access to document 10.1097/CMR.0000000000000421 document
BRAF mutational testing has become a common practice in the diagnostic process of patients with advanced melanoma. Although time-consuming, DNA sequencing techniques are the current gold standard for mutational testing. However, in certain clinical situations, a rapid test result is required. In this study, the performance of three rapid BRAF mutation tests was compared. Thirty-nine formalin-fixed paraffin-embedded melanoma tissue samples collected between 2007 and 2014 at a single center were included. These samples were analyzed by immunohistochemistry using the anti-BRAF-V600E (VE1) mouse monocolonal antibody (BRAF-VE1 IHC), a V600E-specific...
Cornelis Bisschop, Arja Ter Elst, Lisette J Bosman, Inge Platteel, Mathilde Jalving, Anke van den Berg, Arjan Diepstra, Bettien van Hemel, Gilles F H Diercks, Geke A P Hospers, Ed Schuuring
Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma
Published in: Histopathology
Access to document 10.1111/his.13445 document
As an immune escape mechanism tumor cells may downregulate expression of Human Leukocyte Antigens (HLA). Loss of HLA class I and class II has been described in various subtypes of diffuse large B cell lymphoma (DLBCL), including the not otherwise specified (NOS) subgroup. 1,2 We analyzed HLA class I and class II expression in DLBCL not otherwise specified (NOS) to investigate whether there is an association between HLA expression, cell of origin (COO) and the recently reported FOXP1 expression in non-GCB DLBCL. 3 This article is protected by...
L E van der Meeren, Lydia Visser, A Diepstra, M Nijland, A van den Berg, P M Kluin
Relapse in stage I(E) diffuse large B-cell lymphoma
Published in: HEMATOLOGICAL ONCOLOGY
Access to document 10.1002/hon.2487 document
Despite a general favourable outcome in limited stage diffuse large B-cell lymphoma (DLBCL), relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar to the outcome after relapse in advanced stages. From January 2004 through December 2012, all newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical databases to investigate the relapse pattern and outcome in relation to initial treatment and...
Marcel Nijland, Karin Boslooper, Gustaaf van Imhoff, Robbie Kibbelaar, Peter Joosten, Huib Storm, Eric N van Roon, Arjan Diepstra, Hanneke C Kluin-Nelemans, Mels Hoogendoorn